跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/JPRN-jRCT1050220041
JPRN-jRCT1050220041招募中未知

Observational Study to follow up patients enrolled in Prospective clinical study of comprehensive genomic profiling for patients with chemotherapy-naive advanced cancer (FIRST-Dx trial).

Muto Manabu0 个研究点目标入组 180 人开始时间: 2022年6月9日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
180
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
>= 20age old 至 ot applicable（—）

入选标准

  • •1. Registered in FIRST-Dx trial, and underwent F1CDx.
  • •2. Written informed consent.

排除标准

  • •1. Withdrawal of informed consent.
  • •2. Registered in FIRST-Dx trial, but failed in F1CDx.
  • •3. Inappropriate case judged by investigators.

研究者

发起方
Muto Manabu

相似试验

进行中（未招募）
不适用
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis - RESTORE™ SIntravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)MedDRA version: 9.0Level: LLTClassification code 10045365
EUCTR2005-004105-28-GRPDL BioPharma, Inc.300
进行中（未招募）
不适用
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative ColitisIntravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)MedDRA version: 9.0Level: LLTClassification code 10045365
EUCTR2005-004105-28-NLPDL BioPharma, Inc300
进行中（未招募）
不适用
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis - RESTORE™ S
EUCTR2005-004105-28-DEPDL BioPharma, Inc.300
进行中（未招募）
不适用
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis - RESTORE™ S
EUCTR2005-004105-28-FRPDL BioPharma, Inc.300
进行中（未招募）
不适用
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis.
EUCTR2005-004105-28-GBPDL BioPharma, Inc.300